Form 4: Recursion Pharmaceuticals Director Sells 30,000 Shares

Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Director Blake Borgeson executed the sale of 30,000 shares of Class A Common Stock.
• The shares were sold at a price of $3.68 per share.
• The transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025.
• Following the transaction, the director retains beneficial ownership of 6,169,863 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 mechanism, which is standard practice for corporate insiders.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The transaction represents a divestment of equity by a company director.

Risks

• Continued insider selling may be perceived negatively by retail investors as a lack of confidence in short-term price appreciation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common in the biotechnology sector and typically reflects personal financial planning rather than a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to liquidate positions while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the sale represents a small fraction of the director's total holdings.

Next Steps

• Monitor future Form 4 filings for additional insider activity.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Biotech, Equity Sale